Merck KGaA 3Q Sales, Earnings Rose; Fine-Tunes 2022 Outlook
10 November 2022 - 8:04AM
Dow Jones News
By Cecilia Butini
Merck KGaA on Thursday posted rising earnings and sales for the
third quarter and revised its outlook for 2022, raising it for the
life-science business while cutting the forecast for its
electronics arm.
The German healthcare and technology company posted after-tax
profit of 926 million euros ($927.3 million) for the period, up
from EUR764 million the year prior. Adjusted earnings before
interest, taxes, depreciation, and amortization--a closely-watched
metric that strips off some one-off items and which the company
refers to as Ebitda pre--was EUR1.81 billion, up from EUR1.55
billion in the previous year.
Analysts had expected after-tax profit to be EUR988 million and
Ebitda pre at EUR1.80 billion.
Sales were EUR5.81 billion, up from EUR4.97 billion in the third
quarter of 2021.
Merck lifted its forecast for the life-science business and
lowered it for the electronics division. It said it confirmed the
mid point of the absolute range for sales, Ebitda pre and EPS at
group level.
Total company sales are now expected in the range between EUR22
billion and EUR22.9 billion, slighly up from a previous guidance
range of between EUR21.9 billion and EUR23 billion. Ebitda pre is
expected in a range of between EUR6.80 billion and EUR7.20 billion,
up from a previous guidance range of between EUR6.75 billion to
EUR7.25 billion, Merck said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 10, 2022 01:49 ET (06:49 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Merck KGaA (PK) (OTCMarkets): 0 Nachrichtenartikel
Weitere Merck KGaA (PK) News-Artikel